Advertisement

Topics

US court upholds ruling that J&J's Remicade patent is invalid

06:52 EST 24 Jan 2018 | Pharmafile

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis drug Remicade (infliximab) is invalid, upholding a previous decision by the US Patent and Trademark Office (PTO) that the antibodies covered by the patent were already disclosed in an earlier patent.

read more

Original Article: US court upholds ruling that J&J's Remicade patent is invalid

NEXT ARTICLE

More From BioPortfolio on "US court upholds ruling that J&J's Remicade patent is invalid"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...